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Sera from patients with untreated psoriasis were 
found to induce increased superoxide anion (02) gener-
ation when incubated with normal granulocytes (PMNs) 
and zymosan. Sera from patients receiving systemic 
chemotherapy induced O2 generation which was similar 
to that of normal sera and significantly lower than sera 
from the untreated patients. O2 production was mea-
sured by superoxide dismutase inhibitable ferricyto-
chrome C reduction and was dependent on the presence 
of both zymosan and a heat labile serum factor. Serum 
C3c and C5 levels were elevated in both treated and 
untreated groups of psoriasis patients while C4 was 
elevated only in untreated patients. Serum ceruloplas-
min, a O2 scavenger, was not decreased in patients with 
psoriasis, and consequently does not account for the 
increased O2 generation. These data suggest that sera 
from patients with psoriasis have an increased capacity 
to activate PMNs. Activation of PMNs in cutaneous and 
joint lesions may playa pathogenic role in psoriasis. 
The effects of psoriasis are not all confined to the skin. 
Extracutaneous manifestations of psoriasis include functional 
alterations of the immurie system such as circulating immune 
complexes [1] and abnormal T cell function [2-4]. Polymorpho-
nuclear leukocytes (PMNs), which may function as immune 
effector cells, constitute a characteristic component of the epi-
dermal infIltrate in psoriasis [5], and attention has recently 
been paid to assessing PMN function in patients with psoriasis 
and psoriatic arthritis. Wahba and co-workers [6] have shown 
increased in vitro chemotaxis and phagocytosis by peripheral 
blood PMNs from patients with psoriasis. We have reported [7] 
increased in vitro adherence to nylon fIber by circulating PMNs 
from psoriasis patients. In that study, PMN adherence corre-
lated with the extent of disease and wa.s highest in patients who 
also had psoriatic arthritis. One interpretation of these obser-
vations is that certain factors, such as those which are chemo-
tactic for PMNs [8-10], diffuse from cutaneous lesions into the 
circulation where they then affect the function of circulating 
PMNs. To determine whether psoriatic serum may alter PMN 
function, we have measured superoxide anion (0 '2 ) generation 
by PMNs stimulated with zymosan and psoriasis serum. 
Superoxide anion is a highly reactive free radical generated 
Manuscript received March 7, 1980; accepted for publication August 
13, 1980. 
This work was supported by a Cancer Immunology Training Grant 
(NIH CA09082); Arthritis Foundation Clinical Studies Center Grant; 
Dermatology Foundation Grant; NIH Research Grants (AM25563 and 
HL2506) and USPHS Program Project Grant (AM09989). 
Reprint requests to: Paul R. Bergstresser,M.D., Division of Der. 
matology, Univ. of Texas Health Science Center, 5323 Harry Hines 
Boulevard, Dallas, Texas 75235. 
Abbreviations: 
C: serum complement 
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STZ: serum treated zymosan 
ZAS: zymosan activated serum 
on PMN cell membranes as a result of stimulation by soluble 
or particulate materials [11-13]. After stimulation, a respiratory 
burst results in the one-electron reduction of molecular O2 to 
0 "2 via a membrane enzyme system and the coupled oxidation 
of NAD(P)H to NAD(P)+ [14]. Generated 0 '2 dismutates 
spontaneously or enzymatically to form potent oxidants such 
as hydrogen peroxide (H20 2), hydroxyl radical (OH·) and sin-
glet oxygen C02) [15-18]. These oxidants provide the PMN 
with an important mechanism for tissue destruction and bac-
tericidal activity [19-21]' To measure 0 '2 generation, scavengers 
such as ferricytochl"Ome C or nitroblue tetrazolium (NBT) are 
introduced into the reaction system. The quantity of reduced 
cytochrome C or NBT then reflects O2 production since spon-
taneous dismutation has been bypassed. 
Two cytoplasmic enzymes, superoxide dismutase and cata-
lase, protect cellular contents against the oxidizing activity of 
this system by destroying 0 "2 and H 20 2 respectively [19,22, 
23]. When these oxidants are released into the extracellular 
space, as seen .with incomplete phagocytosis or in the absence 
of extracellular scavengers such as ceruloplasmin [24], auto-
oxidation of surrounding tissues may result. Such processes 
may be important in psoi'iasis in which PMNs are deposited 
within the epidermis and in psoriatic arthritis in which PMNs 
are present in the synovial fluid [25]. 
Our results demonstrate that sera from psoriasis patients 
conferred on normal PMNs an increased 0 "2 generating capacity 
when stimulated with zymosan. Sera from patients receiving 
systemic chemotherapy generated normal levels of 0 '2 . Such 
PMN stimulation was dependent on the presence in the reac-
tion of both zymosan and a heat labile serum factor. These 
results suggest that an increased capacity for PMN activation 
is a feature of psoriasis. 
MATERIALS AND METHODS 
Patients 
Twenty-five patients were selected from a county hospital derma-
tology outpatient clinic (Parkland Memorial Hospital) and from a 
medical school dermatology outpatient clinic. Patients were selected at 
random to represent a continuum of disease severity. Seventeen pa-
tients were receiving no treatment prior to or at the time of study. 
Eight patients were receiving systemic chemotherapy: methotrexate-
4; azath ioprine-2, hydroxyurea-I , and colchicine and probenecid-I. 
Controls 
Twenty healthy volunteer subjects without a history of psoriasis or 
chronic skin disease were used as normal controls. Informed consent 
was obtained from all patients and volunteer subjects prior to veni-
puncture. 
Serum Preparation 
Blood obtained by venipuncture was allowed to clot for 30 min at 
room temperature and centrifuged 20 min at 750 g and 4°C. Serum was 
a liquoted immediately and stored at -70°C. On the day of the experi-
ment, samples to be tested were thawed and centrifuged for 60 min at 
100,000 G and 4°C to remove lipids. 
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PMN Purification 
Heparinized (Vacutainer 34716 Becton-Dickinson, Rutherford, N.J .) 
blood was collected from normal cont.rols by venipuncture. PMNs we.re 
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p ur ified from whole blood by ficoll -hypaque gradient (lsolymph, Gal-
lard-Schlesinger Chern., Carle Place, N.Y.), dextran sedimentation and 
h ypotonic lysis of erythl'ocytes. The purified PMNs (>95%) were sus-
pended (2 x 107/ ml) in a balanced salt buffer [26] conta ining 138 mM 
NaCl, 2.7 mM KCI, 8.1 mM Na,HPO", 1.5 mM KH,PO", 0.6 mM CaCb 
and 1.0 mM MgCl" pH 7.4. This buffe r was used in a ll experiments. 
In several experiments PMNs were pretreated with cytochalasin B,5 
J-Lg/ml (Sigma Chemical Co., St. Louis, Mo. ) in 0.1% dimethyl sulfoxide 
(Sigma Chemica l Co.) at 37°C for 5 min before addition of the cell 
aliquots to the reaction mixture. This concentration of dimethyl sul f-
oxide did not influence cytochrome C reduction. 
Sup eroxide Generation 
The assay for 0 " generation was modified fro m Goldstein et al [26]. 
Reaction mixtures (final volume of 7 ml) were prepared by a series of 
timed addit ions. Buffe r and 0. 7 ml serum (10% of final mixtUl'e) were 
m ixed in a 25 ml Erlenmeyer flask and placed in a 37°C shaking 
waterbath. 0.7 ml of 1 mM ferricytochrome C (Horsehear t cytochl'ome 
C T ype VI, Sigma Chemical Co.) was added and in exactly 5 min, 2 X 
10" PMNs (0. 1 ml) were added. Five minutes after addi tion of PMNs, 
0.7 ml of 10 mg/ml zymosan (Sigma Chemical Co.) was mixed in to the 
reaction and a 1 ml aliquot was immediately removed (zero time) . 
Addit ional aliquots were removed from the reaction mixtw'e at 5 min 
in tervals. The reaction was terminated by placing the aliquots on ice, 
after which they were centrifuged for 2.5 min a t 12,800 g (Eppendorf, 
Micro Model 54 12, Brinkman Instruments, WestbUl'Y, N.Y.) and re-
turned to the ice bath. Reduced cytochrome C in the cell -free super-
nates was measured at 550 nm on a double beam spectrophotometer 
(Model 25, Beckman Instruments, Palo Al to, CAl against a blank of 
10% cytochl'ome C (1 mM) in buffer. Reduced cytochrome C was 
q u antitated using an extinction coefficient of 21.1 mM - 1 em- I at 550 nm 
(reduced-oxidized) [27,28]' Specificity of cytochrome C reduction was 
verified by adding 0.7 ml of 150 fLg/ml supel'oxide dismu tase (SOD) 
(Bovine, Sigma Chemical Company) to the reaction mixture at the 
same time as the serum and proceeding as above. Cytochrome C 
reduction in reaction mixtures wi thout serum was also measured and 
fo und not to be significantly influenced by any of the other reagents. 
O2 genera tion was expressed as nmoles cytochrome C reduced per 2 
x 10" PMNs. 
Serum Treated Zymosan 
Zymosan (10 mg) was pretreated with 1 ml of' normal 0 1' psoriasis 
sera fo r 30 min at 37°C. After centrifugation the zymosan activated 
serum (ZAS) was removed and the serum treated zymosan (STZ) was 
washed and resuspended in buffer (10 mg/ml) . Serum and zymosan 
were omitted from the reaction mixture when ZAS or STZ were added 
at zero t ime. 
Complement L evels 
Serum complement (C) levels were determined by radial immuno-
diffusion. M-P al'tigen C4 and C3c ki ts were obtained from Behring 
Diagnostics, Somerville, N.J . C5 determination kits were obta ined from 
Meloy Laboratories, Springfield, Va. 
Ceruloplasm in L evels 
Serum ceruloplasmin activi ty was measured by oxidase activity 
according to the method of Schosinsky, Lehmann, and Beeler [29]. In 
this method, o-dianisidine dihydrochloride is conver ted to a colored 
reaction product which is then measured spectrophotometrically. Its 
usefulness fo r this study lies in the fact that the activity of ceruloplas-
min as an enzyme (oxidase activity) is precisely that of a superoxide 
scavenger [24]. 
Statistics 
Both pal'ametric (Student's t- test) and nonparametl'ic (Mann Whi t-
. Dey U-test) analyses were used to determine the significance of differ-
ences between psoriatic and control groups. The resul ts of both meth-
ods were similar. 
RES ULTS 
S uperoxide genera tion by normal P MNs suspended in pso-
riasis or control sera is illustrated in F ig 1. M ean cytochrome C 
reduction in t h e presence of sera from 20 normal con trols 
increased in a n a pproxima tely linear fashion between 5 a nd 25 
min after zym osan addition. In contrast, sera from 17 unt reated 
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FIG I. S uperox ide ge nera ti on by norma l PMNs incubated wi t h 
zy mosa n a nd norm a l (---) or pso ri as is (un t reated-
treated · ... . . . ) sera as measured by cytochrome C reduction. 
psorias is patients produced high er a m ounts of r educed cyto-
chronie C beginning at 5 min. The diffe ren ce between normal 
volunteers and psoriasis patien ts was s ignifican t ( p < .004, 
M a nn Whit ney U -test) by 10 min a nd increased wit h su bse-
quen t m easurem ents reaching 58.9 ± 1.6 (M ean ± S EM) vs 43 .1 
± 2.4 nmoles (p < .001) at 25 min. 
M ean cytochrom e C reduction in sera from 8 patients receiv-
ing sys temic ch emotherapy (Fig 1) was not significa ntly di ffer-
ent from t h e n ormal cont ro ls at each of the assayed reaction 
times. Since from 1 to 7 serum samples were collected during 
t reatment for ea ch of t h ese patients, th e cytochrom e C redu c-
t ion resul ts for each treated patien t were a veraged to give a 
single m ean value per patient. Cytochrome C reduction for t h e 
t r ea ted patients was less t h a n th at of untreated patie nts wi th 
s ignifican t differen ces OCCUlTing at 20 ( p < .01) a nd 25 min ( p 
< .002) . 
Increased 0 '2 release by P MNs in sera from psoriasis patien ts 
might take place if such sera inhibited t h e ph agocytosis of 
zymosan . Wit h decr eased phagocytosis less cell surface m em-
bra n e would be internalized into phagosom es, and m ore 0 '2 
would reach t h e extracellular space, giving a n appear a nce of 
increased a nion genera tion. T o test t his possibility, PMNs were 
pre treated wi t h cytochalasin B as previously reported [26,30] 
to eliminate t h e effect of phagocytosis on 0 '2 generation . Cy-
tochrom e C reduction induced by sera from psor iasis patien ts 
r em ained significantly increased when compar ed wit h reduction 
induced by normal sera (Ta ble I) . 
0 '2 generation was dependent on th e p resen ce of both zy-
m osan a nd a heat la bile serum factor. W h en zym osan was 
omitted from t h e reaction mixt Ul'e, cytochrom e C r eduction 
a nd therefore 0 '2 gen era tion for both normal a nd psoriasis sera 
r em a ined at baseline levels (Ta ble II) . When normal or psoriasis 
sera were heat inac tivated a t 56°C for 30 min prior to a ddit ion 
to the reaction, t h e cytoclu'ome C reduction again r em ained at 
baseline (FigUl'e 1). 
Incr eased 0 '2 activation m ay be due to altered soluble serum 
factors or a n increased opsonization of zym osan . In paralle l 
experimen ts, P MNs wer e activated with serum a nd zym osan 0 )' 
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TABLE 1. Effect of cytochalasin B on cytochrom e C reduction 
Time (min) 
n 
5 10 15 20 25 
Normal controls 6 1.9" 10.2 21.1 30.8 38.3 
Psoriasis Patients 6 5.1 22.1 36.4 47.6 56.5 
p value nsf, <.004 <.003 <.002 < .001 
PMNs were pretreated 5 min at 37 0 with 5 Ilg/ ml cytochalasin B in 
0.1% DMSO. 
" nmoles cytochrome C reduced per 2 x 10H PMNs. 
b Not significant. 
TABLE II. Effect of zymosan on cytochrome C reduction 
Time (min) 
n 
5 10 15 20 25 
With zymosan 
Normal Controls 20 3.3" 12.0 23.3 33.7 43.1 
Psoriasis Patients 
Untreated 17 4.7 19.6 35.2 49.0 58.9 
Treated 8 4.0 16.0 27.5 39.0 47.4 
Without zymosan 
Normal Controls 9 1.3 2.7 3.9 5.5 7.3 
Psoriasis Patients 12 1.6 2.7 4.5 5.9 8.2 
" nmoles cytochrome C reduced per 2 x lOG PMNs. 
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FIG 2. Effect of normal (---) or psoriasis (- - -) zymosan 
activated serum (ZAS) and serum treated zymosan (STZ) on cyto-
chrome C reduction by normal PMNs. Cells were incubated with serum 
and zymosan (e); ZAS (.&), or STZ (0 ). 
the corresponding ZAS or STZ (Fig 2). ConfIrming OUT previous 
results, 6 psoriasis sera, when added in conjunction with zy-
mosan, induced higher cytochrome C reduction compared with 
5 normal sera. The ZAS from the same 6 patients resulted in 
baseline cytochrome C reduction that was not different from 
normal ZAS activation. STZ from both groups gave cytochrome 
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C reduction above baseline but there was no significant differ-
ence between normal and psoriasis STZ activation. 
To determine whether cytochrome C reduction reflected 0 2: 
generation alone, SOD was added to the reaction mixture. SOD 
accelerates the dismutation of 0 2: to H 20 2 and O2, bypassing 
cytochrome C reduction, although reduction of cytochrome C 
by an independent mechanism would be unaffected. Data in 
Fig 3 demonstrate that reduced cytochrome C remained at 
baseline levels for both normal and psoriasis sera in the presence 
of SOD. It was concluded that increased cytochrome C reduc-
tion by PMNs in psoriasis serum reflected only increased 0 2: 
generation. 
The effect of serum dilution on 0 2: generation was assessed 
by decreasing serum concentrations in the reaction mixture 
from 10% to 5% and 2.5% (Fig 4). Normal serum was sensitive 
to dilution and cytochrome C reduction dropped to baseline 
amounts when 5% rather than 10% serum was added. Psoriasis 
serum diluted to 5% in the reaction mixture gave only a 25% 
decrease in cytochrome C reduction compared to the 10% 
concentration (51.3 vs 68.6 nmoles). Significant amounts of 0 2: 
were still generated with the 2.5% psoriasis serum (only a 74% 
decrease). The effect of dilution was to magnify the difference 
between psoriasis and control sera. Therefore, those factors 
which are responsible for the increase in 0 2: generation by 
psoriatic serum are present in relative excess. 
PMN activation by zymosan is dependent on opsonization by 
complement (C) components of the alternative pathway [21, 
26]. Since changes in C factor concentrations may alter 0 "2 
production, serum levels of C3c, C5 and C4 were measured by 
radial immunodiffusion. 
Alternate C pathway activation proceeds through the cleav-
age of C3 to form C3b, an opsonin of zymosan. Mean serum 
C3c of 33 untreated psoriasis patients (99.0 ± 4.2 mg/dl) was 
significantly (p < .03) higher than that of 22 normal controls 
(85.8 ± 2.9 mg/dl) (Fig 5). Six patients receiving systemic 
chemotherapy had a mean serum C3c of 111.1 ± 8.3 mg/dl, also 
elevated above that of the normal controls (p < .01). 
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duction by normal PMNs incubated with zymosan and normal 
(---) or psoriasis (- - -) sera. 
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FIG 4. Effect of serum dilution on cytochrome C reduction by nor-
mal PMNs incubated with zymosan and normal (---) or psoriatic 
( __ -) serum. The serum concentration in the reaction mixture was 
diluted from 10% to 5% and 2.5%. 
In addition to C3b opsonized zymosan, alterate C pathway 
activation liberates C5a, a possible PMN stimulant [21,26]. 
Thirty-five untreated psoriasis patients had a mean selUm C5 
concen tration of 13.1 ± 0.4 mg/dl compared with the mean of 
22 normal controls of 11.4 ± 0.4 mg/ ill (p < .02) and the mean 
of 6 treated patients of 13.2 ± 0.8 mg/ dl (ns) (Fig 6). 
Since both C3 and C5 are components of the alternate 
pathway, serum C4 was measured to determine whether a 
classical pathway component is also altered in these patients. 
Forty-eight untreated psoriasis patients had a mean selUm C4 
level of 56.3 ± 3.0 mg/ ill as compared with 21 normal controls 
at 39.0 ± 3.0 mg/ ill (p < .001) and 6 t reated patients at 43.2 ± 
4.6 mg/ ill (p < .04) (Fig 7) . 
Serum ceruloplasmin was measured in 12 patients with un-
treated psoriasis and in 12 sex-matched control subjects. Ceru-
loplasmin activity was 162 ± 13 Units/ liter in patients with 
psoriasis and 137 ± 10 units/ liter in control subjects (ns) . When 
stratified by sex, means were 180 ± 18 and 145 ± 18 units/liter 
for 6 female and 6 male patients respectively, compared with 
157 ± 14 and 127± 6 units/ liter for female and male control 
subjects respectively. Although mean values for patients were 
consistently above those of the normal subjects, no differences 
were significant. 
DISCUSSION 
Increasing evidence indicates that PMN function is altered 
in patients with psoriasis. Circulating PMNs OCCUI' in increased 
numbers [7]; they exhibit increased in vitro adherence [7], 
increased chemotaxis and phagocytosis [6], and they possess 
abnormal cell surface morphology [31]. These changes may be 
due to inherent PMN alterations as suggested by Wahba et al 
[6] or they may result from interaction with a solu ble circulating 
factor(s) . 
Changes in PMN function may playa role in the pathogenesis 
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of psoriasis. PMNs are present in cutaneous lesions [5] and 
synovial fluid [25] of patients with psoriasis and psoriatic a1'-
thTitis. Activation of PMNs in t hese areas may cause auto-
oxidation and tissue destruction. McCord [32] has suggested a 
possible mechanism for in vivo synovial fluid degTadation in 
inflamed joints. He found that enzymatically generated O2 
degrades bovine synovial fluid and prepa1'ations of purified 
hyaluronic acid. Rister and co-workers [33] have observed a 
SOD deficiency in PMNs from children with rheumatoid ar-
t hritis, suggesting that decreased enzymatic dismutation of O2 
produces the synovial fluid deterioration found in inflammatory 
arthl'itis conditions. A similar mechanism in psoriasis and pso-
riatic arthTit is would give a pathogenic role to the inftltrating 
PMNs. 
PMNs generate O2 on their cell membrane when stimulated 
by zymosan in t he presence of serum. In our studies, sera from 
untreated psoriasis patients were found to have an increased 
capacity to stimulate PMNs fTOm normal volunteers when 
compared to normal sera. Sera from patients receiving systemic 
chemotherapy had lost this increased capacity and O2 genera-
tion remained at normal levels. Pretreatment of PMNs with 
cytochalasin B resulted in no dimunition of the difference 
between cytochTome C reduction by normal and psoriasis sera 
suggesting that inhibition of phagocytosis was not occurring in 
sera from psoriasis patients. The addition of SOD inhibited 
cytochl'ome C reduction such that only baseline levels were 
achieved with both normal and psoriatic sera. Therefore, in-
creased cytochl'ome C reduction by the psoriatic sera appeared 
to result from increased O2 generation and not from other 
mechanisms of reduction. 
O2 generation was found to be dependent on a heat labile 
selUm factor. Since zymosan is thought to stimulate PMNs 
thTough its opsonization by C and since heat inactivation de-
stroys C activity, the O2 production appears to be C dependent. 
Activated C, probably C5a, has been reported to induce endo-
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thelial cell damage by PMN generation of O2 [21]. C3b can also 
stimulate PMNs b.y opsonization of zymosan [26]. Sera from 
untreated psoriasis patients were found to contain increased 
concentrations of C3c and C5, components of both the alternate 
and classical pathways. C4, a classical pathway component, was 
also significantly increased in psoriatic serum suggesting that 
psoriasis patients have a general increase in C components. It 
is possible then, that increased O2 generation by psoriatic 
serum reflects an increase in C components. The decrease in 
O2 production with systemic chemotherapy may likewise re-
flect a decrease in serum C. This decrease presumably would 
result from suppression of the disease process with a corre-
sponding drop in C production. Such a decrease was found only 
for C4, the classical pathway component. The levels of C3e and 
C5 were not decreased with treatment. Since the classical 
pathway has been shown to participate in zymosan activation 
of the alternate pathway [34], the elevated C41evels in psoriasis 
patients may provide an amplification of the alternate pathway 
activation and subsequently of O2 generation. 
O2 generation· was found to be dependent on the presence of 
both serum and zymosan in the reaction mixture. Since this 
combination leads to the generation of 2 activators, opsonized 
zymosan and soluble C factors, such as C5a, zymosan and serum 
were pretreated and the resulting soluble and particulate frac-
tions separated. Neither ZAS nor STZ induced significantly 
increased cytochrome C reduction when sera from normal 
controls and psoriasis patients were compared. It is therefore 
possible that the preactivation procedure resulted in significant 
degradation ofthe active C components and a loss in subsequent 
activity. . 
The role C plays in the pathogenesis of psoriasis is not yet 
known, but it is clearly established that factors released during 
C activation alter PMN adherence [35,36] chemotaxis [34,37] 
and O2 generation [21,26]. Consequently, our findings of ele-
vated C levels in psoriasis suggest that such patients possess an 
increased capacity for PMN activation via the C pathways. 
Factors released from psoriatic lesions, such as the PMN che-
Vol. 76, No.3 
motactic factor found in psoriatic scales [8-10], may have more 
generalized effects and not be confined to the epidermis and 
joints. Such factors or circulating immune complexes [1] are 
capable of altering PMN function by acting on the cell directly 
or through C activation. The resulting alterations in PMN 
function could enhance their capacity to participate in the 
cutaneous changes and joint destruction seen in psoriasis and 
psoriatic arthritis. 
Increased O2 generation may also occur if psoriasis sera fail 
to scavenge O2 properly. Ceruloplasmin, a copper containing 
plasma protein, mimics the dismutative activity of SOD, a 
copper containing cytoplasmic enzyme, as it inhibits the reduc-
tion of both ferricytochrome C and NBT by enzymatically 
generated O2 [24]. For this reason ceruloplasmin has been 
postulated to provide a mechanism of extracellular protection 
against auto-oxidation. 
Serum ceruloplasmin was determined in 12 untreated pa-
tients by the enzymatic reduction of o-dianisidine dihydrochlo-
ride, an assay which measures ceruloplasmin oxidative capacity 
[29]. Since it is by oxidation that ceruloplasmin enhances O2 
degradation, this assay is a direct measure of serum capacity to 
protect the extracellular space from oxidative injury [24]. Mean 
serum ceruloplasmin values for 12 patients were slightly ele-
vated as compared with 12 sex-matched control subjects but 
the difference was not significant. For other reasons and by 
other assays, serum ceruloplasmin has previously been deter-
mined in psoriasis. Using the enzymatic reduction of p-phen-
ylenediamine, Kekki, Koskelo, and Lassus [38] reported normal 
levels of ceruloplasmin in patients with uncomplicated psoriasis, 
while Zlatkov, Bozhkov, and Genov [39] reported that similar 
patients had significantly increased levels with the same assay 
system. These data, plus our own, demonstrate that serum 
ceruloplasmin activity is certainly not decreased in patients 
with psoriasis and that the capacity of such serum to elicit 
increased production of O2 must occm by a different mecha-
nism. 
Additional studies will be required to determine the exact 
-0 
'-01 
E 
<:j" 
u 
100 
80 
60 
40 
20 
r--p<OOOl-----, 
• 
• 
• 
• 
• 
• 
• 
:1 
• 
••• 
.. 
.. 
... 
• 
!!: 
.. 
--'-
.-
-
.. 
.. 
.... 
.... 
• 
• 
• 
o~ ____ ~ ______ ~ ____ __ 
Normal 
Controls 
Psoriasis 
Patients 
FIG· 7. Serum C4 as determined by radial immunodiffusion for nor-
mal controls and patients with psoriasis. 
March 1981 
mech anism responsible for the observed enhancement of O2 
generation which is induced by serum from patients with pso-
riasis. 
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